



(86) Date de dépôt PCT/PCT Filing Date: 1994/10/21
 (87) Date publication PCT/PCT Publication Date: 1995/04/27
 (45) Date de délivrance/Issue Date: 2006/05/23
 (85) Entrée phase nationale/National Entry: 1996/04/09
 (86) N° demande PCT/PCT Application No.: US 1994/012117
 (87) N° publication PCT/PCT Publication No.: 1995/011221
 (30) Priorités/Priorities: 1993/10/22 (US08/141,248);
 1994/08/19 (US08/292,827)



(51) Cl.Int./Int.Cl. *C07C 217/58* (2006.01),
C07C 323/32 (2006.01), *C07C 255/58* (2006.01),
C07C 219/28 (2006.01), *C07C 215/50* (2006.01),
C07C 211/27 (2006.01), *A61K 31/36* (2006.01),
A61K 31/275 (2006.01), *A61K 31/165* (2006.01),
A61K 31/135 (2006.01), *A61K 31/13* (2006.01),
C07C 211/30 (2006.01), *C07C 211/29* (2006.01),
C07C 217/62 (2006.01), *C07C 237/30* (2006.01),
C07D 317/58 (2006.01)

(72) Inventeurs/Inventors:
 NEMETH, EDWARD F., US;
 BALANDRIN, MANUEL F., US;
 DELMAR, ERIC G., US;

...

(54) Titre : ARYLALKYLAMINES AGISSANT SUR LES RECEPTEURS DU CALCIUM

(54) Title: CALCIUM RECEPTOR-ACTIVE ARYLALKYL AMINES



(57) Abrégé/Abstract:

The present invention features molecules with general structure (I) or (II) which can modulate on or activities of an inorganic ion receptor. Preferably, the molecule can mimic or block the effect of extracellular Ca²⁺ on a calcium receptor. The preferred use of such molecules is to treat diseases or disorders by altering inorganic ion receptor activity, preferably calcium receptor activity.

(72) Inventeurs(suite)/Inventors(continued): MOE, SCOTT T., US; VAN WAGENEN, BRADFORD C., US

(73) Propriétaires(suite)/Owners(continued):NPS PHARMACEUTICALS, INC., US



(74) Agent: SMART & BIGGAR



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07C 211/30, 217/62, 217/58, 323/32, A61K 31/13		A1	(11) International Publication Number: WO 95/11221
			(43) International Publication Date: 27 April 1995 (27.04.95)
(21) International Application Number: PCT/US94/12117		(71) Applicant (for all designated States except US): NPS PHARMACEUTICALS, INC. [US/US]; 420 Chipeta Way, Salt Lake City, UT 84108 (US).	
(22) International Filing Date: 21 October 1994 (21.10.94)		(72) Inventors; and	
(30) Priority Data: 08/141,248 22 October 1993 (22.10.93) US 08/292,827 19 August 1994 (19.08.94) US		(75) Inventors/Applicants (for US only): NEMETH, Edward, F. [US/US]; 3258 East Fortuna Drive, Salt Lake City, UT 84124 (US). VAN WAGENEN, Bradford, C. [US/US]; 3969 South 3250 East, Salt Lake City, UT 84124 (US). BALANDRIN, Manuel, F. [US/US]; 9184 South Wren Drive, Sandy, UT 84093 (US). DELMAR, Eric, G. [US/US]; 2967 East St. Mary's Circle, Salt Lake City, UT 84108 (US). MOE, Scott, T. [US/US]; 6152 South Vinefield Drive, Salt Lake City, UT 84121 (US).	
(60) Parent Applications or Grants (63) Related by Continuation		(74) Agents: HEBER, Sheldon, O. et al.; Lyon & Lyon, First Interstate World Center, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071-2066 (US).	
US 07/749,451 (CIP) Filed on 23 August 1991 (23.08.91)		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ).	
US 07/834,044 (CIP) Filed on 11 February 1992 (11.02.92)		<p style="text-align: center;">2173747</p> <p>Published With international search report.</p>	
US 07/934,161 (CIP) Filed on 21 August 1992 (21.08.92)			
US 08/017,127 (CIP) Filed on 12 February 1993 (12.02.93)			
US 08/009,389 (CIP) Filed on 23 February 1993 (23.02.93)			
US 08/141,248 (CIP) Filed on 22 October 1993 (22.10.93)			
US 08/292,827 (CIP) Filed on 19 August 1994 (19.08.94)			

(54) Title: CALCIUM RECEPTOR-ACTIVE ARYLALKYL AMINES



(57) Abstract

The present invention features molecules with general structure (I) or (II) which can modulate on or activities of an inorganic ion receptor. Preferably, the molecule can mimic or block the effect of extracellular Ca^{2+} on a calcium receptor. The preferred use of such molecules is to treat diseases or disorders by altering inorganic ion receptor activity, preferably calcium receptor activity.

2173747

1

DESCRIPTION

Calcium receptor-active arylalkyl amines

FIELD OF THE INVENTION

This invention relates to the design, development, composition and use of novel molecules able to modulate the activity of inorganic ion receptor.

BACKGROUND OF THE INVENTION

5 Certain cells in the body respond not only to chemical signals, but also to ions such as extracellular calcium ions (Ca^{2+}). Changes in the concentration of extracellular Ca^{2+} (referred to herein as " $[\text{Ca}^{2+}]$ ") alter the functional responses of these cells. One such
10 specialized cell is the parathyroid cell which secretes parathyroid hormone (PTH). PTH is the principal endocrine factor regulating Ca^{2+} homeostasis in the blood and extracellular fluids.

PTH, by acting on bone and kidney cells, increases
15 the level of Ca^{2+} in the blood. This increase in $[\text{Ca}^{2+}]$ then acts as a negative feedback signal, depressing PTH secretion. The reciprocal relationship between $[\text{Ca}^{2+}]$ and PTH secretion forms the essential mechanism maintaining bodily Ca^{2+} homeostasis.

20 Extracellular Ca^{2+} acts directly on parathyroid cells to regulate PTH secretion. The existence of a parathyroid cell surface protein which detects changes in $[\text{Ca}^{2+}]$ has been confirmed. Brown et al., 366 Nature 574, 1993. In parathyroid cells, this protein acts as a receptor for
25 extracellular Ca^{2+} ("the calcium receptor"), and detects changes in $[\text{Ca}^{2+}]$ and to initiate a functional cellular response, PTH secretion.

Extracellular Ca^{2+} can exert effects on different cell functions, reviewed in Nemeth et al., 11 Cell Calcium 319,
30 1990. The role of extracellular Ca^{2+} in parafollicular (C-cells) and parathyroid cells is discussed in Nemeth, 11 Cell Calcium 323, 1990. These cells have been shown to express similar Ca^{2+} receptor. Brown et al., 366 Nature 574, 1993; Mithal et al., 9 Suppl. 1 J. Bone and Mineral

Res. s282, 1994; Rogers *et al.*, 9 Suppl. 1 J. Bone and Mineral Res. s409, 1994; Garrett *et al.*, 9 Suppl. 1 J. Bone and Mineral Res. s409, 1994. The role of extracellular Ca^{2+} on bone osteoclasts is discussed by

5 Zaidi, 10 Bioscience Reports 493, 1990. In addition keratinocytes, juxtaglomerular cells, trophoblasts, pancreatic beta cells and fat/adipose cells all respond to increases in extracellular calcium which likely reflects activation of calcium receptors of these cells.

10 The ability of various compounds to mimic extracellular Ca^{2+} *in vitro* is discussed by Nemeth *et al.*, (spermine and spermidine) in "Calcium-Binding Proteins in Health and Disease," 1987, Academic Press, Inc., pp. 33-35; Brown *et al.*, (e.g., neomycin) 128

15 Endocrinology 3047, 1991; Chen *et al.*, (diltiazem and its analog, TA-3090) 5 J. Bone and Mineral Res. 581, 1990; and Zaidi *et al.*, (verapamil) 167 Biochem. Biophys. Res. Commun. 807, 1990. Nemeth *et al.*, PCT/US93/01642, International Publication Number WO 94/18959, and Nemeth

20 *et al.*, PCT/US92/07175, International Publication Number WO 93/04373, describe various compounds which can modulate the effect of an inorganic ion on a cell having an inorganic ion receptor, preferably modulate the effects of calcium on a calcium receptor.

25 The references provided in the background are not admitted to be prior art.

SUMMARY OF THE INVENTION

The present invention features molecules which can modulate one or activities of an inorganic ion receptor.

30 Preferably, the molecule can mimic or block the effect of extracellular Ca^{2+} on a calcium receptor. The preferred use of such molecules is to treat diseases or disorders by altering inorganic ion receptor activity, preferably calcium receptor activity.

35 Extracellular Ca^{2+} is under tight homeostatic control and controls various processes such as blood clotting, nerve and muscle excitability, and proper bone formation.

Calcium receptor proteins enable certain specialized cells to respond to changes in extracellular Ca^{2+} concentration. For example, extracellular Ca^{2+} inhibits the secretion of parathyroid hormone from parathyroid cells, inhibits bone
5 resorption by osteoclasts, and stimulates secretion of calcitonin from C-cells.

Compounds modulating inorganic ion receptor activity can be used to treat diseases or disorders by affecting one or more activities of an inorganic ion receptor
10 resulting in a beneficial effect to the patient. For example, osteoporosis is an age related disorder characterized by loss of bone mass and increased risk of bone fracture. Compounds blocking osteoclastic bone resorption either directly (e.g., a osteoclast ionmimetic
15 compound) or indirectly by increasing endogenous calcitonin levels (e.g., a C-cell ionmimetic), and/or by decreasing parathyroid hormone levels (e.g., a parathyroid cell ionmimetic) can retard bone loss and, thus, result in beneficial effects to patients suffering from
20 osteoporosis.

In addition, it is known that intermittent low dosing with PTH results in an anabolic effect on bone mass and appropriate bone remodeling. Thus, compounds and dosing regiments evoking transient increases in parathyroid
25 hormone (e.g., intermittent dosing with a parathyroid cell ionlytic) can increase bone mass in patients suffering from osteoporosis.

Additionally, diseases or disorders characterized by a defect in one or more inorganic ion receptor activities
30 may be treated by the present invention. For example, certain forms of primary hyperparathyroidism are characterized by abnormally high levels of parathyroid hormone and decreased parathyroid gland responsiveness to circulating calcium. Calcium receptor modulating agents
35 can be used to modulate parathyroid cell responsiveness to calcium.

Preferably, the compound modulates calcium receptor activity and is used in the treatment of diseases or disorders which can be affected by modulating one or more activities of a calcium receptor. Preferably, the disease or disorder is characterized by abnormal bone and mineral homeostasis, more preferably calcium homeostasis.

Abnormal calcium homeostasis is characterized by one or more of the following activities: (1) an abnormal increase or decrease in serum calcium; (2) an abnormal increase or decrease in urinary excretion of calcium; (3) an abnormal increase or decrease in bone calcium levels, for example, as assessed by bone mineral density measurements; (4) an abnormal absorption of dietary calcium; and (5) an abnormal increase or decrease in the production and/or release of circulating messengers or hormones which affect calcium homeostasis such as parathyroid hormone and calcitonin. The abnormal increase or decrease in these different aspects of calcium homeostasis is relative to that occurring in the general population and is generally associated with a disease or disorder.

More generally, a molecule which modulates the activity of an inorganic ion receptor is useful in the treatment of diseases characterized by abnormal inorganic ion homeostasis. Preferably, the molecule modulates one or more effects of an inorganic ion receptor. Inorganic ion receptor modulating agents include ionmimetics, ionlytics, calcimimetics, and calcilytics.

Ionmimetics are molecules which mimic the effects of increasing ion concentration at an inorganic ion receptor. Preferably, the molecule affects one or more calcium receptor activities. Calcimimetics are ionmimetics which affect one or more calcium receptor activities and preferably binds to a calcium receptor.

Ionlytics are molecules which reduce or block one or more activities caused by an inorganic ion on an inorganic ion receptor. Preferably, the molecule inhibits one or


79565-6

5

more calcium receptor activities. Calcilytics are ionlytics which inhibit one or more calcium receptor activities evoked by extracellular calcium and preferably bind to a calcium receptor.

5 Inorganic ion receptor modulating agents can be formulated as pharmacological agents or compositions to facilitate administration in a patient. Pharmacological agents or compositions are agents or compositions in a form suitable for administration into a mammal, preferably a
10 human. Considerations concerning forms suitable for administration are known in the art and include toxic effects, solubility, route of administration, and maintaining activity.

Thus, a first aspect of the invention is a novel
15 compound (*i.e.*, an inorganic ion receptor modulating agent) which either evokes one or more inorganic ion receptor activities, or blocks one or more inorganic ion receptor activity caused by an extracellular inorganic ion. The compound has the formula:



25

where each X is independently selected from the group consisting of isopropyl, CH₃O, CH₃S, CF₃O, an aliphatic ring and an attached or fused aromatic ring; and

each m is independently between 0 and 5 inclusive.

30 Preferably, the aromatic and aliphatic rings have 5 to 7 members. More preferably, the aromatic and aliphatic


79565-6

6

rings contain only carbon atoms (*i.e.*, the ring is not a heterocyclic ring).

Preferably, the molecule either evokes one or more calcium receptor activities, or blocks one or more calcium receptor activities caused by extracellular calcium.

Preferably, the formula (I) is represented by the formula:




wherein:

each Y is independently selected from the group consisting of isopropyl, CH₃O, CH₃S and a fused aromatic ring; and

n is independently an integer between 0 and 5 inclusive.


Preferably, when X is the fused aromatic ring,



Another aspect of the present invention features a novel compound (*i.e.*, an inorganic ion receptor modulating agent) having the formula:

79565-6

7



where each X independently is selected from the
 10 group consisting of H, CH₃, CH₃O, CH₃CH₂O, methylene dioxy,
 Br, Cl, F, CF₃, CHF₂, CH₂F, CF₃O, CH₃S, OH, CH₂OH, CONH₂, CN,
 NO₂, CH₃CH₂, propyl, isopropyl, butyl, isobutyl, t-butyl,
 acetoxy, aliphatic ring and an attached or fused aromatic
 ring;

15 each R independently is selected from the group
 consisting of hydrogen, methyl, ethyl, propyl, isopropyl,
 butyl, allyl, isobutyl, t-butyl, cyclopentyl, cyclohexyl,
 cycloheptyl, cyclooctyl, indenyl, indanyl, dihydroindolyl,
 thiodihydroindolyl, and 2-, 3-, or 4- piperid(in)yl; and

20 each m is independently between 0 and 5 inclusive.

The molecule either evokes one or more inorganic
 ion receptor activities, or blocks one or more inorganic ion
 receptor activities, caused by an extracellular inorganic
 ion. Preferably, the molecule either evokes one or more
 25 calcium receptor activities, or blocks one or more calcium
 receptor activities caused by extracellular calcium.

In preferred embodiments R is either H, CH₃, ethyl,
 or isopropyl, and each X is independently selected from the
 group consisting of isopropyl, CH₃O, CH₃S, CF₃O, aliphatic
 30 ring and an attached or fused aromatic ring. Preferably,
 the aliphatic ring and attached or fused aromatic ring have


72459-13

7a

5 to 7 members. More preferably, the aromatic and aliphatic rings contain only carbon atoms.

Preferably, the formula (II) is represented by the formula:

5



wherein:


each Y is independently selected from the group consisting of CH₃, CH₃O, CH₃CH₂O, methylene dioxy, Br, Cl, F, CF₃, CH₃S, OH, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl and a fused aromatic ring;

R is hydrogen or methyl; and

each n is independently an integer between 0 and 5 inclusive, provided that (a) when R is H and n is 2, Y is not CH₃O and Br; or (b) when R is H and n is 2, Y is not CH₃CH₂O and Cl.


Preferably, when X is the fused aromatic ring,

20




72459-13


7b




5



In a preferred aspect, the invention relates to
 10 compounds having the chemical formula:



15



or the pharmaceutically acceptable salts or complexes thereof.

20

Another aspect of the present invention features an inorganic ion receptor modulating agent comprising a molecule selected from the group consisting of compound 4L, compound 8J, compound 8U, compound 9R, compound 11X,

72459-13

7c

compound 12U, compound 12V, compound 12Z, compound 14U,
compound 16M and compound 16P.

Other aspects of the present invention feature
pharmaceutical compositions and methods of using the agents
5 described herein for treating diseases or disorders by
modulating inorganic ion receptor activity. Patients in
need of such treatments can be identified by standard
medical techniques, such as routine blood analysis. For
example, by detecting a deficiency of protein whose
10 production or secretion is affected by changes in inorganic
ion concentrations, or by detecting abnormal levels of
inorganic ions or hormones which effect inorganic ion
homeostasis.

Pharmaceutical compositions contain
15 pharmaceutically acceptable carriers in addition to the
agents described above. Pharmaceutical compositions of the
invention may be contained in a commercial package, together
with instructions for the use thereof.

Therapeutic methods involve administering to the
20 patient a therapeutically effective amount of an inorganic
ion receptor modulating agent. In preferred embodiments
these methods are used to treat a disease or disorder
characterized by abnormal inorganic ion homeostasis, more
preferably a disease or disorder characterized by abnormal
25 calcium homeostasis. Diseases and disorders characterized
by abnormal calcium homeostasis include hypertension,
hyperparathyroidism (especially of the primary or secondary
type), hypercalcemia, osteoporosis, Paget's disease, and
other bone and mineral-related disorders, and the like (as
30 described, e.g., in standard medical text books, such as
"Harrison's Principles of Internal Medicine"). Such
diseases and disorders are treated using calcium receptor

72459-13

7d

modulating agents which mimic or block one or more of the effects of Ca^{2+} and, thereby, directly or indirectly affect the levels of proteins or other molecules in the body of the patient.

- 5 By "therapeutically effective amount" is meant an amount of an agent which relieves to some extent one or more symptoms of the disease or disorder in the patient; or returns to normal either partially or completely one or

2173747

8

more physiological or biochemical parameters associated with or causative of the disease or disorder.

In a preferred embodiment, the patient has a disease or disorder characterized by an abnormal level of one or more calcium receptor regulated components and the molecule is active on a calcium receptor of a cell selected from the group consisting of parathyroid cell, bone osteoclast, juxtaglomerular kidney cell, proximal tubule kidney cell, distal tubule kidney cell, central nervous system cell, peripheral nervous system cell, cell of the thick ascending limb of Henle's loop and/or collecting duct, keratinocyte in the epidermis, parafollicular cell in the thyroid (C-cell), intestinal cell, trophoblast in the placenta, platelet, vascular smooth muscle cell, cardiac atrial cell, gastrin-secreting cell, glucagon-secreting cell, kidney mesangial cell, mammary cell, beta cell, fat/adipose cell, immune cell and GI tract cell.

More preferably, the cell is a parathyroid cell and the molecule reduces the level of parathyroid hormone in the serum of the patient, even more preferably the level is reduced to a degree sufficient to cause a decrease in plasma Ca^{2+} , most preferably the parathyroid hormone level is reduced to that present in a normal individual.

Thus, the present invention features agents and methods useful in the treatment of diseases and disorders by modulating inorganic ion receptor activity. For example, the molecules of the present invention can be used to target calcium receptors on different cell types that detect and respond to changes to external calcium. For example, molecules mimicking external calcium may be used to selectively depress secretion of parathyroid hormone from parathyroid cells, or depress bone resorption by osteoclasts, or stimulate secretion of calcitonin from C-cells. Such molecules can be used to treat diseases or disorders characterized by abnormal calcium homeostasis such as hyperparathyroidism and osteoporosis.

79565-6

9/1

Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof and from the claims.

BRIEF DESCRIPTION OF THE DRAWING

5 Figs. 1A-D, 2A-D, 3A-E, 4A-E, 5A-D, 6A-E, 7A-E, 8A-E, 9A-F, 10A-D, 11A-E, 12A-D, 13A-D, 14A-D, 15A-D, 16A-D, 17A-D, 18A-E, 19A-D, and 20A-D show the chemical structures of molecules derived from diphenylpropyl- α -phenethylamine illustrating a family of molecules which were prepared and
10 screened to find the useful molecules of the invention.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention describes inorganic ion receptor modulating agents able to mimic or block an effect of an inorganic ion at an inorganic ion receptor. The
15 preferred use of inorganic ion receptor modulating agents is to treat a disease or disorder by modulating inorganic ion receptor activity. Preferably, the molecules are used to treat diseases or disorders characterized by abnormal ion homeostasis, more preferably abnormal calcium homeostasis.
20 Other uses of inorganic ion receptor modulating agents, such as diagnostics uses, are known in the art. Nemeth *et al.*, PCT/US93/01642, International Publication Number WO 94/18959.

I. CALCIUM RECEPTORS

25 Calcium receptors and nucleic acid encoding calcium receptors are described by Nemeth *et al.*, PCT/US93/01642, International Publication Number WO 94/18959. Calcium receptors are present on different cell types such as parathyroid cell, bone osteoclast,
30 juxtaglomerular kidney cell, proximal tubule kidney cell,

79565-6

9/1a

distal tubule kidney cell, central nervous system cell,
peripheral nervous system cell, cell of the thick ascending
limb of Henle's loop and/or collecting duct, keratinocyte in
the epidermis, parafollicular cell in the thyroid (C-cell),
5 intestinal cell, trophoblast in the placenta, platelet,
vascular smooth muscle cell, cardiac atrial cell, gastrin-

23 JAN 1995

15.02.95

9/2

2173747

secreting cell, glucagon-secreting cell, kidney mesangial cell, mammary cell, beta cell, fat/adipose cell, immune cell, and GI tract cell. The calcium receptor on these

RECTIFIED SHEET (RULE 91)

AMENDED SHEET

cell types may be different. It is also possible that a cell can have more than one type of calcium receptor.

Comparison of calcium receptor activities and amino acid sequences from different cells indicate that distinct calcium receptor types exist. For example, calcium receptors can respond to a variety of di- and trivalent cations. The parathyroid calcium receptor responds to calcium and Gd^{3+} , while osteoclasts respond to divalent cations such as calcium but does not respond to Gd^{3+} . Thus, the parathyroid calcium receptor is pharmacologically distinct from calcium receptor on the osteoclast.

On the other hand, the nucleic acid sequences encoding calcium receptors present in parathyroid cells and C-cells indicate that these receptors have a very similar amino acid structure. Nevertheless, calcimimetic compounds exhibit differential pharmacology and regulate different activities at parathyroid cells and C-cells. Thus, pharmacological properties of calcium receptors may vary significantly depending upon the cell type or organ in which they are expressed even though the calcium receptors may have similar structures.

Calcium receptors, in general, have a low affinity for extracellular Ca^{2+} (apparent K_d generally greater than about 0.5 mM). Calcium receptors may include a free or bound effector mechanism as defined by Cooper, Bloom and Roth, "The Biochemical Basis of Neuropharmacology", Ch. 4, and are thus distinct from intracellular calcium receptors, e.g., calmodulin and the troponins.

Calcium receptors respond to changes in extracellular calcium levels. The exact changes depend on the particular receptor and cell line containing the receptor. For example, the *in vitro* effect of calcium on the calcium receptor in a parathyroid cell include the following:

1. An increase in internal calcium. The increase is due to the influx of external calcium and/or

mobilization of internal calcium. Characteristics of the increase in internal calcium include the following:

(a) A rapid (time to peak < 5 seconds) and transient increase in $[Ca^{2+}]_i$ that is refractory to inhibition by $1 \mu M La^{3+}$ or $1 \mu M Gd^{3+}$ and is abolished by pretreatment with ionomycin (in the absence of extracellular Ca^{2+});

(b) The increase is not inhibited by dihydropyridines;

(c) The transient increase is abolished by pretreatment for 10 minutes with 10 mM sodium fluoride;

(d) The transient increase is diminished by pretreatment with an activator of protein kinase C (PKC), such as phorbol myristate acetate (PMA), mezerein or (-)-indolactam V. The overall effect of the protein kinase C activator is to shift the concentration-response curve to calcium to the right without affecting the maximal response; and

(e) Treatment with pertussis toxin (100 ng/ml for > 4 hours) does not affect the increase.

2. A rapid (< 30 seconds) increase in the formation of inositol-1,4,5-triphosphate or diacylglycerol. Treatment with pertussis toxin (100 ng/ml for > 4 hours) does not affect this increase;

3. The inhibition of dopamine- and isoproterenol-stimulated cyclic AMP formation. This effect is blocked by pretreatment with pertussis toxin (100 ng/ml for > 4 hours); and

4. The inhibition of PTH secretion. Treatment with pertussis toxin (100 ng/ml for > 4 hours) does not affect the inhibition in PTH secretion.

Using techniques known in the art, the effect of calcium on other calcium receptors in different cells can be readily determined. Such effects may be similar in regard to the increase in internal calcium observed in parathyroid cells. However, the effect is expected to

differ in other aspects, such as causing or inhibiting the release of a hormone other than parathyroid hormone.

II. INORGANIC ION RECEPTOR MODULATING AGENTS

Inorganic ion receptor modulating agents either evokes one or more inorganic ion receptor activities, or blocks one or more inorganic ion receptor activities caused by an extracellular inorganic ion. Calcium receptor modulating agents can mimic or block an effect of extracellular Ca^{2+} on a calcium receptor. Preferred calcium receptor modulating agents are calcimimetics and calcilytics. Generic and specific structures of inorganic ion receptor modulating agents are provided in the Summary *supra*, and in Figure 1.

Inorganic ion receptor modulating agents can be identified by screening molecules which are modelled after a molecule shown to have a particular activity (*i.e.*, a lead molecule). Nemeth et al., PCT/US93/01642, International Publication Number WO 94/18959.

Preferred inorganic ion receptor modulation agents described by the present invention are compounds are 8J, 8U, 9R, 11X, 12U, 12V, 12Z, 14U, 16M, and 16P. These compounds all have EC_{50} values of less than 5 μM .

The EC_{50} is the concentration of the molecule which evokes a half-maximal effect. The IC_{50} is the concentration of molecule which causes a half-maximal blocking effect. The EC_{50} or IC_{50} can be determined by assaying one or more of the activities of an inorganic ion at an inorganic ion receptor. Preferably, such assays are specific to a particular calcium receptor. For example, assays which measure hormones whose production or secretion is modulated by a particular inorganic ion receptor are preferred.

Increases in $[\text{Ca}^{2+}]_i$ can be detected using standard techniques such as by using fluorimetric indicators or by measuring an increase in Cl^- current in a *Xenopus* oocyte injected with nucleic acid coding for a calcium receptor. Nemeth et al., PCT/US93/01642, International Publication

Number WO 94/18959. For example, poly(A)⁺ mRNA can be obtained from cells expressing a calcium receptor, such as a parathyroid cell, bone osteoclast, juxtaglomerular kidney cell, proximal tubule kidney cell, distal tubule kidney cell, cell of the thick ascending limb of Henle's loop and/or collecting duct, keratinocyte in the epidermis, parafollicular cell in the thyroid (C-cell), intestinal cell, central nervous cell, peripheral nervous system cell, trophoblast in the placenta, platelet, vascular smooth muscle cell, cardiac atrial cell, gastrin-secreting cell, glucagon-secreting cell, kidney mesangial cell, mammary cell, beta cell, fat/adipose cell, immune cell, and GI tract cell. Preferably, the nucleic acid is from a parathyroid cell, C-cell, or osteoclast. More preferably, the nucleic acid encodes a calcium receptor and is present on a plasmid or vector.

Preferably, the molecule is either a calcimimetic or calcilytic having an EC₅₀ or IC₅₀ at a calcium receptor of less than or equal to 5 μM, and even more preferably less than or equal to 1 μM, 100 nmolar, 10 nmolar, or 1 nmolar. Such lower EC₅₀'s or IC₅₀'s are advantageous since they allow lower concentrations of molecules to be used *in vivo* or *in vitro* for therapy or diagnosis. The discovery of molecules with such low EC₅₀'s and IC₅₀'s enables the design and synthesis of additional molecules having similar potency and effectiveness.

In preferred embodiments the calcium receptor modulating agent is a calcimimetic which inhibits parathyroid hormone secretion from a parathyroid cell *in vitro* and decreases PTH secretion *in vivo*; stimulates calcitonin secretion from a C-cell *in vitro* and elevates calcitonin levels *in vivo*; or blocks osteoclastic bone resorption *in vitro* and inhibits bone resorption *in vivo*.

In another preferred embodiment the calcium receptor modulating agent is a calcilytic which evokes the secretion of parathyroid hormone from parathyroid cells *in*

vitro and elevates the level of parathyroid hormone *in vivo*.

Preferably, the agent selectively targets inorganic ion receptor activity, more preferably calcium receptor activity, in a particular cell. By "selectively" is meant that the molecule exerts a greater effect on inorganic ion receptor activity in one cell type than at another cell type for a given concentration of agent. Preferably, the differential effect is 10-fold or greater. Preferably, the concentration refers to blood plasma concentration and the measured effect is the production of extracellular messengers such as plasma calcitonin, parathyroid hormone or plasma calcium. For example, in a preferred embodiment, the agent selectively targets PTH secretion over calcitonin secretion.

In another preferred embodiment, the molecule has an EC_{50} or IC_{50} less than or equal to $5 \mu M$ at one or more, but not all cells chosen from the group consisting of parathyroid cell, bone osteoclast, juxtaglomerular kidney cell, proximal tubule kidney cell, distal tubule kidney cell, cell of the thick ascending limb of Henle's loop and/or collecting duct, central nervous system cell, peripheral nervous system cell, keratinocyte in the epidermis, parafollicular cell in the thyroid (C-cell), intestinal cell, trophoblast in the placenta, platelet, vascular smooth muscle cell, cardiac atrial cell, gastrin-secreting cell, glucagon-secreting cell, kidney mesangial cell, mammary cell, beta cell, fat/adipose cell, immune cell and GI tract cell.

Preferably, inorganic ion receptor modulating agents mimic or block all of the effects of extracellular ion in a cell having an inorganic ion receptor. For example, calcium receptor modulating agents preferably mimic or block all of the effects of extracellular ion in a cell having a calcium receptor. Calcimimetics need not possess all the biological activities of extracellular Ca^{2+} , but, rather, at least one such activity is mimicked.

Similarly, calcilytics need not reduce or prevent all of the activities caused by extracellular calcium. Additionally, different calcimimetics and different calcilytics do not need to bind to the same site on the calcium receptor as does extracellular Ca^{2+} to exert their effects.

A. Calcimimetics

The ability of molecules to mimic or block the activity of Ca^{2+} at calcium receptors can be determined using procedures known in the art and described by Nemeth *et al.*, PCT/US93/01642, International Publication Number WO 94/18959. For example, calcimimetics possess one or more and preferably all of the following activities when tested on parathyroid cells *in vitro*:

1. The molecule causes a rapid (time to peak < 5 seconds) and transient increase in $[\text{Ca}^{2+}]_i$ that is refractory to inhibition by $1 \mu\text{M}$ La^{3+} or $1 \mu\text{M}$ Gd^{3+} . The increase in $[\text{Ca}^{2+}]_i$ persists in the absence of extracellular Ca^{2+} but is abolished by pretreatment with ionomycin (in the absence of extracellular Ca^{2+});

2. The molecule potentiates increases in $[\text{Ca}^{2+}]_i$ elicited by submaximal concentrations of extracellular Ca^{2+} ;

3. The increase in $[\text{Ca}^{2+}]_i$ elicited by extracellular Ca^{2+} is not inhibited by dihydropyridines;

4. The transient increase in $[\text{Ca}^{2+}]_i$ caused by the molecule is abolished by pretreatment for 10 minutes with 10 mM sodium fluoride;

5. The transient increase in $[\text{Ca}^{2+}]_i$ caused by the molecule is diminished by pretreatment with an activator of protein kinase C (PKC), such as phorbol myristate acetate (PMA), mezerein or (-)-indolactam V. The overall effect of the protein kinase C activator is to shift the concentration-response curve of the molecule to the right without affecting the maximal response;

6. The molecule causes a rapid (< 30 seconds) increase in the formation of inositol-1,4,5-triphosphate and/or diacylglycerol;

7. The molecule inhibits dopamine- or isoproterenol-stimulated cyclic AMP formation;

8. The molecule inhibits PTH secretion;

9. Pretreatment with pertussis toxin (100 ng/ml for > 4 hours) blocks the inhibitory effect of the molecule on cyclic AMP formation but does not effect increases in $[Ca^{2+}]_i$, inositol-1,4,5-triphosphate, or diacylglycerol, nor decreases in PTH secretion;

10. The molecule elicits increases in Cl^- current in *Xenopus* oocytes injected with poly(A)⁺-enriched mRNA from bovine or human parathyroid cells, but is without effect in *Xenopus* oocytes injected with water, or rat brain or liver mRNA; and

11. Similarly, using a cloned calcium receptor from a parathyroid cell, the molecule will elicit a response in *Xenopus* oocytes injected with the specific cDNA or mRNA encoding the receptor.

Different calcium activities can be measured using available techniques. Nemeth et al., PCT/US93/01642, International Publication Number WO 94/18959. Parallel definitions of molecules mimicking Ca^{2+} activity on other calcium responsive cell, preferably at a calcium receptor, are evident from the examples provided herein and Nemeth et al., PCT/US93/01642, International Publication Number WO 94/18959.

Preferably, the agent as measured by the bioassays described herein, or by Nemeth et al., PCT/US93/01642, International Publication Number WO 94/18959, has one or more, more preferably all of the following activities: evokes a transient increase in internal calcium, having a duration of less than 30 seconds (preferably by mobilizing internal calcium); evokes a rapid increase in $[Ca^{2+}]_i$, occurring within thirty seconds; evokes a sustained increase (greater than thirty seconds) in $[Ca^{2+}]_i$;

(preferably by causing an influx of external calcium); evokes an increase in inositol-1,4,5-triphosphate or diacylglycerol levels, preferably within less than 60 seconds; and inhibits dopamine- or isoproterenol-stimulated cyclic AMP formation.

The transient increase in $[Ca^{2+}]_i$ is preferably abolished by pretreatment of the cell for ten minutes with 10 mM sodium fluoride, or the transient increase is diminished by brief pretreatment (not more than ten minutes) of the cell with an activator of protein kinase C, preferably, phorbol myristate acetate (PMA), mezerein or (-) indolactam V.

B. Calcilytics

The ability of a molecule to block the activity of external calcium can be determined using standard techniques. Nemeth et al., PCT/US93/01642, International Publication Number WO 94/18959. For example, molecules which block the effect of external calcium, when used in reference to a parathyroid cell, possess one or more, and preferably all of the following characteristics when tested on parathyroid cells *in vitro*:

1. The molecule blocks, either partially or completely, the ability of increased concentrations of extracellular Ca^{2+} to:

- (a) increase $[Ca^{2+}]_i$;
- (b) mobilize intracellular Ca^{2+} ,
- (c) increase the formation of inositol-1,4,5-triphosphate,
- (d) decrease dopamine- or isoproterenol-stimulated cyclic AMP formation, and
- (e) inhibit PTH secretion;

2. The molecule blocks increases in Cl^- current in *Xenopus* oocytes injected with poly(A)⁺ mRNA from bovine or human parathyroid cells elicited by extracellular Ca^{2+} or calcimimetic compounds, but not in *Xenopus* oocytes injected with water or liver mRNA;

3. Similarly, using a cloned calcium receptor from a parathyroid cell, the molecule will block a response in *Xenopus* oocytes injected with the specific cDNA, mRNA or cRNA encoding the calcium receptor, elicited
5 by extracellular Ca^{2+} or a calcimimetic compound.

Parallel definitions of molecules blocking Ca^{2+} activity on a calcium responsive cell, preferably at a calcium receptor, are evident from the examples provided herein and Nemeth et al., PCT/US93/01642, International
10 Publication Number WO 94/18959..

III. TREATMENT OF DISEASES OR DISORDERS

A preferred use of the compounds described by the present invention is in the treatment or prevention of different diseases or disorders by modulating inorganic
15 ion receptor activity. The inorganic ion receptor modulating agents of the present invention can exert an affect on a inorganic ion receptor causing one or more cellular effects ultimately producing a therapeutic effect.

20 Different diseases and disorders can be treated by the present invention by targeting cells having an inorganic ion receptor, such as a calcium receptor. For example, primary hyperparathyroidism (HPT) is characterized by hypercalcemia and elevated levels of
25 circulating PTH. A defect associated with the major type of HPT is a diminished sensitivity of parathyroid cells to negative feedback regulation by extracellular Ca^{2+} . Thus, in tissue from patients with primary HPT, the "set-point" for extracellular Ca^{2+} is shifted to the right so that
30 higher than normal concentrations of extracellular Ca^{2+} are required to depress PTH secretion. Moreover, in primary HPT, even high concentrations of extracellular Ca^{2+} often depress PTH secretion only partially. In secondary (uremic) HPT, a similar increase in the set-point for
35 extracellular Ca^{2+} is observed even though the degree to which Ca^{2+} suppresses PTH secretion is normal. The changes in PTH secretion are paralleled by changes in $[\text{Ca}^{2+}]_i$: the

2173747

set-point for extracellular Ca^{2+} -induced increases in $[\text{Ca}^{2+}]_i$ is shifted to the right and the magnitude of such increases is reduced.

Molecules that mimic the action of extracellular Ca^{2+} are beneficial in the long-term management of both primary and secondary HPT. Such molecules provide the added impetus required to suppress PTH secretion which the hypercalcemic condition alone cannot achieve and, thereby, help to relieve the hypercalcemic condition. Molecules with greater efficacy than extracellular Ca^{2+} may overcome the apparent nonsuppressible component of PTH secretion which is particularly troublesome in adenomatous tissue. Alternatively or additionally, such molecules can depress synthesis of PTH, as prolonged hypercalcemia has been shown to depress the levels of preproPTH mRNA in bovine and human adenomatous parathyroid tissue. Prolonged hypercalcemia also depresses parathyroid cell proliferation *in vitro*, so calcimimetics can also be effective in limiting the parathyroid cell hyperplasia characteristic of secondary HPT.

Cells other than parathyroid cells can respond directly to physiological changes in the concentration of extracellular Ca^{2+} . For example, calcitonin secretion from parafollicular cells in the thyroid (C-cells) is regulated by changes in the concentration of extracellular Ca^{2+} .

Isolated osteoclasts respond to increases in the concentration of extracellular Ca^{2+} with corresponding increases in $[\text{Ca}^{2+}]_i$ that arise partly from the mobilization of intracellular Ca^{2+} . Increases in $[\text{Ca}^{2+}]_i$ in osteoclasts are associated with the inhibition of bone resorption. Release of alkaline phosphatase from bone-forming osteoblasts is directly stimulated by calcium.

Renin secretion from juxtaglomerular cells in the kidney, like PTH secretion, is depressed by increased concentrations of extracellular Ca^{2+} . Extracellular Ca^{2+} causes the mobilization of intracellular Ca^{2+} in these cells. Other kidney cells respond to calcium as follows:

2173747

20

elevated Ca^{2+} inhibits formation of $1,25(\text{OH})_2$ -vitamin D by proximal tubular cells, stimulates production of calcium-binding protein in distal tubular cells, and inhibits tubular reabsorption of Ca^{2+} and Mg^{2+} and the action of vasopressin on the medullary thick ascending limb of Henle's loop (MTAL), reduces vasopressin action in the cortical collecting duct cells, and affects vascular smooth muscle cells in blood vessels of the renal glomerulus.

10 Calcium also promotes the differentiation of intestinal goblet cells, mammary cells, and skin cells; inhibits atrial natriuretic peptide secretion from cardiac atria; reduces cAMP accumulation in platelets; alters gastrin and glucagon secretion; acts on vascular smooth
15 muscle cells to modify cell secretion of vasoactive factors; and affects cells of the central nervous system and peripheral nervous system.

Thus, there are sufficient indications to suggest that Ca^{2+} , in addition to its ubiquitous role as an
20 intracellular signal, also functions as an extracellular signal to regulate the responses of certain specialized cells. Molecules of this invention can be used in the treatment of diseases or disorders associated with disrupted Ca^{2+} responses in these cells.

25 Specific diseases and disorders which might be treated or prevented, based upon the affected cells, also include those of the central nervous system such as seizures, stroke, head trauma, spinal cord injury, hypoxia-induced nerve cell damage such as in cardiac
30 arrest or neonatal distress, epilepsy, neurodegenerative diseases such as Alzheimer's disease, Huntington's disease and Parkinson's disease, dementia, muscle tension, depression, anxiety, panic disorder, obsessive-compulsive disorder, post-traumatic stress disorder, schizophrenia,
35 neuroleptic malignant syndrome, and Tourette's syndrome; diseases involving excess water reabsorption by the kidney such as syndrome of inappropriate ADH secretion (SIAH),

cirrhosis, heart failure, and nephrosis; hypertension; preventing and/or decreasing renal toxicity from cationic antibiotics (e.g., aminoglycoside antibiotics); gut motility disorders such as diarrhea, and spastic colon; GI
5 ulcer diseases; GI absorption diseases such as sarcoidosis; and autoimmune diseases and organ transplant rejection.

While inorganic ion receptor modulating agents of the present invention will typically be used in therapy for
10 human patients, they may be used to treat similar or identical diseases or disorders in other warm-blooded animal species such as other primates, farm animals such as swine, cattle, and poultry; and sports animals and pets such as horses, dogs and cats.

15 IV. ADMINISTRATION

The molecules of the invention can be formulated for a variety of modes of administration to treat patients by modulating inorganic ion receptor activity. Techniques and formulations for administration of compounds generally
20 may be found in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA. Administration of ionmimetics and ionlytics is discussed by Nemeth et al., PCT/US93/01642, International Publication Number WO 94/18959.

25 Suitable forms, in part, depend upon the use or the route of entry, for example oral, transdermal, or by injection. Such forms should allow the agent to reach a target cell whether the target cell is present in a multicellular host or in culture. For example,
30 pharmacological agents or compositions injected into the blood stream should be soluble in the concentrations used. Other factors are known in the art, and include considerations such as toxicity and forms which prevent the agent or composition from exerting its effect.

35 Agents can also be formulated as pharmaceutically acceptable salts (e.g., acid addition salts) and complexes thereof. The preparation of such salts can facilitate the

2173747

22

pharmacological use by altering the physical characteristics of the agent without preventing it from exerting its physiological effect. Examples of useful alterations in physical properties include lowering the melting point to facilitate transmucosal administration and increasing the solubility to facilitate administering higher concentrations of the drug.

For systemic administration, oral administration is preferred. Alternatively, injection may be used, e.g., intramuscular, intravenous, intraperitoneal, and subcutaneous. For injection, the molecules of the invention are formulated in liquid solutions, preferably in physiologically compatible buffers such as Hank's solution or Ringer's solution. In addition, the molecules may be formulated in solid form and redissolved or suspended immediately prior to use. Lyophilized forms can also be produced.

Systemic administration can also be by transmucosal or transdermal means, or the molecules can be administered orally. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, bile salts and fusidic acid derivatives. In addition, detergents may be used to facilitate permeation. Transmucosal administration may be through nasal sprays, for example, or using suppositories. For oral administration, the molecules are formulated into conventional oral administration dosage forms such as capsules, tablets, and tonics.

For topical administration, the molecules of the invention are formulated into ointments, salves, gels, or creams, as is generally known in the art.

Generally, a therapeutically effective amount is between about 1 nmole and 3 μ mole of the molecule, preferably 0.1 nmole and 1 μ mole depending on its EC_{50} or IC_{50} and on the age and size of the patient, and the

2173747

23

disease or disorder associated with the patient. Generally it is an amount between about 0.1 and 50 mg/kg, preferably 0.01 and 20 mg/kg, animal to be treated.

V. EXAMPLES

5 The compounds described herein can be synthesized using standard techniques such as those described by Nemeth *et al.*, PCT/US93/01642, International Publication Number WO 94/18959. Examples describing the syntheses of compounds 4L, 8J, 8U, 9R, 11X, 12U, 12V, 12Z, 14U, 16M and
10 16P are provided below. Compounds 4L, 8J, 8U, 11X and 16M were prepared from the condensation of a primary amine with an aldehyde or ketone in the presence of titanium(IV) isopropoxide. The resulting intermediate imines were then reduced *in situ* by the action of sodium cyanoborohydride,
15 sodium borohydride, or sodium triacetoxyborohydride. The intermediate enamine for the synthesis of compound 8U was catalytically reduced using palladium hydroxide.

Synthesis of compounds 9R, 14U, and 16P were prepared by reductive amination of a commercially available
20 aldehyde or ketone with a primary amine in the presence of sodium cyanoborohydride or sodium triacetoxyborohydride. It was found for the syntheses of these three compounds (9R, 14U, and 16P) that sodium triacetoxyborohydride afforded the desired diastereomers with greater
25 diastereoselectivity than using sodium cyanoborohydride. The enriched mixtures were further purified to a single diastereomer by normal-phase HPLC or by recrystallization from organic solvents.

Compounds 12U, 12V and 12Z were prepared by a
30 diisobutylaluminum hydride (DIBAL-H) mediated condensation of an amine with a nitrile. The resulting intermediate imine is reduced *in situ* by the action of sodium cyanoborohydride or sodium borohydride. The intermediate alkenes (compounds 12U and 12V) were reduced by catalytic
35 hydrogenation in EtOH using palladium on carbon. Compounds which were converted to their corresponding

2173747

24

hydrochloride were done so by treatment of the free base with ethereal HCl to afford white solids.

The amines in these syntheses were (1) purchased from Aldrich Chemical Co., Milwaukee, WI, (2) purchased from
5 Celgene Corp., Warren, NJ, or (3) prepared synthetically using standard techniques. All other reagent chemicals were purchased from Aldrich Chemical Co.

Example 1: Synthesis of Compound 4L

N-3-Phenyl-1-propyl-1-(1-naphthyl)ethylamine

10 A mixture of 3-phenyl-1-propylamine (135 mg, 1 mmol), 1'-acetonaphthone (170 mg, 1 mmol), and titanium (IV) isopropoxide (355 mg, 1.3 mmol) was stirred at room temperature for 1 hour. The reaction was treated with 1 M ethanolic sodium cyanoborohydride (1 mL) and stirred at
15 room temperature for 16 hours. The reaction was diluted with ether and treated with water (0.1 mL). The reaction was centrifuged and the ether layer removed and concentrated to a milky oil. A small portion of this material (10 mg) was purified by HPLC (Phenomenex, 1.0 x
20 25 cm, 5 μ M silica) using a gradient of dichloromethane to 10% methanol in dichloromethane containing 0.1% isopropylamine. This afforded the product (free base) as a single component by GC/El-MS (R_t = 10.48 min) m/z (rel. int.) 289 (M^+ , 11), 274 (63), 184 (5), 162 (5), 155 (100),
25 141 (18), 115 (8), 91 (45), 77(5).

Example 2: Synthesis of Compound 8J

N-(3-phenylpropyl)-1-(3-thiomethylphenyl)ethylamine hydrochloride

3'-Aminoacetophenone (2.7 g, 20 mmol) was dissolved
30 in 4 mL of concentrated HCl, 4 g of ice and 8 mL of water. The solution was cooled to 0°C, and sodium nitrite (1.45 g, 21 mmol) dissolved in 3-5 mL of water was added over 5 minutes while maintaining the temperature below 6°C. Sodium thiomethoxide (1.75 g, 25 mmol) was dissolved in 5
35 mL of water and cooled to 0°C. To this solution was added

2173747

25

the diazonium salt over 10 minutes while maintaining the temperature below 10°C. The reaction was stirred for an additional hour while allowing the temperature to rise to ambient. The reaction mixture was partitioned between ether and water. The ether layer was separated and washed with sodium bicarbonate and sodium chloride, and dried over sodium sulfate. The ether was evaporated to give a 74% yield of 3'-thiomethylacetophenone. The crude material was purified by distillation at reduced pressure.

10 3-Phenylpropylamine (0.13 g, 1 mmol), 3'-thiomethylacetophenone (0.17 g, 1 mmol), and titanium (IV) isopropoxide (0.36 g, 1.25 mmol) were mixed together and allowed to stand for 4 hours. Ethanol (1 mL) and sodium cyanoborohydride (0.063 g, 1 mmol) were added and the

15 reaction was stirred overnight. The reaction was worked up by the addition of 4 mL of ether and 200 µL of water. The mixture was vortexed and then spun in a centrifuge to separate the solids. The ether layer was separated from the precipitate, and the solvent removed *in vacuo*. The

20 oil was redissolved in dichloromethane and the compound purified by preparative TLC on silica gel eluted with 3% methanol/dichloromethane to yield the title compound as a pure oil: GC/EI-MS(R_f =7.64 min) m/z (rel. int.) 285 (M^+ , 18), 270(90), 180(17), 151(100), 136(32), 104(17), 91(54),

25 77(13).

Example 3: Synthesis of Compound 8U

N-3-(2-methoxyphenyl)-1-propyl-(*R*)-3-methoxy- α -methylbenzylamine hydrochloride

A mixture of (*R*)-(+)-3-methoxy- α -methylbenzylamine

30 (3.02 g, 20 mmol), 2-methoxycinnamaldehyde (3.24 g, 20 mmol), and titanium (IV) isopropoxide (8.53 g, 30 mmol, 1.5 Eq.) was stirred 2 hours at room temperature and treated with 1 M (20 mL) ethanolic sodium cyanoborohydride. The reaction was stirred overnight (16

35 hours), diluted with diethylether, and treated with water (1.44 mL, 80 mmol, 4 Eq.). After mixing for 1 hour the

2173747

26

reaction mixture was centrifuged and the ether layer removed and concentrated to an oil. This material was dissolved in glacial acetic acid, shaken with palladium hydroxide and hydrogenated under 60 p.s.i. hydrogen for 2
5 hours at room temperature. The catalyst was removed by filtration and the resulting solution concentrated to a thick oil. This material was dissolved in dichloromethane and neutralized with 1 N NaOH. The dichloromethane solution was separated from the aqueous phase, dried over
10 anhydrous potassium carbonate and concentrated to an oil. This material was dissolved in ether and treated with 1 M HCl in diethylether. The resulting precipitate (white solid) was collected, washed with diethylether, and air dried. GC/El-MS ($R_f = 9.69$ min) of this material (free
15 base) showed a single component: m/z (rel. int.) 299 (M+, 21), 284 (100), 164 (17), 150 (8), 135 (81), 121 (40), 102 (17), 91 (43), 77 (18).

Example 4: Synthesis of Compound 9R

(R)-N-(1-(2-naphthyl)ethyl)-(R)-1-(1-naphthyl)ethylamine
20 *hydrochloride*

A mixture of *(R)-(+)-1-(1-naphthyl)ethylamine* (10.0 g, 58 mmol), 2'-acetonaphthone (9.4 g, 56 mmol), titanium (IV) isopropoxide (20.7 g, 73.0 mmol), and EtOH (abs.) (100 mL) was heated to 60°C for 3 hours. Sodium
25 cyanoborohydride (NaCNBH₃) (3.67 g, 58.4 mmol) was then added. The reaction mixture was stirred at room temperature for 18 hours. Ether (1 L) and H₂O (10 mL) were added to the reaction mixture and the resulting precipitate was then removed by centrifugation. The
30 supernatant was evaporated under vacuum and the crude product was recrystallized four times from hot hexane, to provide 1.5 g of pure (98+%) diastereomer. The free base was dissolved in hexane, filtered, and then ethereal HCl was added to precipitate the product as a white solid (1.1
35 g, 6 % yield), m.p.: softens 200-240 °C (dec.).

2173747

27

Example 5: Synthesis of Compound 11X

N-(4-Isopropylbenzyl)-(R)-1-(1-naphthyl)ethylamine hydrochloride

A mixture of (R)-(+)-1-(1-naphthyl)ethylamine (1.06 g, 6.2 mmol), 4-isopropylbenzaldehyde (0.92 g, 6.2 mmol), and titanium (IV) isopropoxide (2.2 g, 7.7 mmol) was heated to 100°C for 5 min then allowed to stir at room temperature for 4 hours. Sodium cyanoborohydride (NaCNBH₃) (0.39 g, 6.2 mmol) was then added followed by EtOH (1 mL). The reaction mixture was stirred at room temperature for 18 hours. Ether (100 mL) and H₂O (1 mL) were added to the reaction mixture and the resulting precipitate was then removed by centrifugation. The supernatant was evaporated under vacuum and the crude product was chromatographed on silica gel (50 mm X 30 cm column) (elution with 1% MeOH/CHCl₃). The chromatographed material was then dissolved in hexane and ethereal HCl was added to precipitate the product as a white solid (0.67 g, 35 % yield), m.p.; 257-259°C.

Example 6: Synthesis of Compound 12U

N-3-(2-methylphenyl)-1-propyl-(R)-3-methoxy- α -methylbenzylamine hydrochloride

A solution of 2-methylcinnamionitrile (1.43 g, 10 mmol) in dichloromethane (10 mL) was cooled to 0°C and treated dropwise (15 minutes) with 1 M diisobutylaluminum hydride (10 mL, dichloromethane). The reaction was stirred at 0°C for 15 minutes and treated dropwise (15 minutes) with a 1 M solution of (R)-(+)-3-methoxy- α -methylbenzylamine (1.51 g, 10 mmol) in dichloromethane (10 mL). The reaction was stirred 1 hours at 0°C and poured into a solution of ethanol (100 mL) containing sodium cyanoborohydride (1 g, 16 mmol). The reaction mixture was stirred 48 hour at room temperature. The reaction was diluted with ether and neutralized with 1 N NaOH. The ether layer was removed, dried over anhydrous potassium carbonate and concentrated to an oil. This material was

2173747

28

chromatographed through silica using a gradient of dichloromethane to 5% methanol in dichloromethane to afford the unsaturated intermediate, a single component by GC/EI-MS ($R_t=10.06$ min) m/z (rel. int.) 281 (M^+ , 17), 266 (59), 176 (19), 146 (65), 135 (73), 131 (100), 91 (21), 77 (13).

The unsaturated intermediate in ethanol was hydrogenated (1 atm H_2) in the presence of palladium on carbon for 16 hours at room temperature. The product from this reaction was converted to the hydrochloride salt by treatment with 1 M HCl in diethylether. GC/EI-MS ($R_t = 9.31$ min) of this material (free base) showed a single component: m/z (rel. int.) 283 (M^+ , 21), 268 (100), 164 (12), 148 (8), 135 (85), 121 (12), 105 (49), 91 (23), 77 (21).

Example 7: Synthesis of Compound 12V

N-3-(3-methylphenyl)-1-propyl-(*R*)-3-methoxy- α -methylbenzylamine hydrochloride

The compound was prepared following the procedure described in Example 6, but using 2-methylcinnamitrile. The unsaturated intermediate was a single component by GC/EI-MS ($R_t = 10.21$ min) m/z (rel. int.) 281 (M^+ , 57), 266 (86), 146 (98), 135 (88), 131 (100), 115 (43), 102 (26), 91 (43), 77 (18). Reduction of this material and hydrochloride formation using the procedure described Example 6 afforded the product. GC/EI-MS ($R_t = 9.18$ min) of this material (free base) showed a single component; m/z (rel. int.) 283 (M^+ , 19), 268 (100), 164 (11), 148 (8), 135 (76), 121 (16), 105 (45), 91 (23), 77 (21).

Example 8: Synthesis of Compound 12Z

N-3-(2-chlorophenyl)-1-propyl-(*R*)-1-(1-naphthyl)ethylamine hydrochloride

The compound was prepared following the procedures described in Example 6, but using 2-chlorohydrocinnamitrile and (*R*)-(+)-1-(1-

79565-6

29

naphthyl)ethylamine on a 10 mmol scale. Chromatography through silica using a gradient of dichloromethane to 5% methanol in dichloromethane afforded the product as a single component by TLC analysis (5% methanol in dichloromethane).
5 The hydrochloride was prepared by treatment with 1 M HCl in diethylether.

Example 9: Synthesis of Compound 14U

(R)-N-(1-(4-methoxyphenyl)ethyl)-(R)-1-(1-naphthyl)ethylamine hydrochloride

10 A mixture of (R)-(+)-1-(1-naphthyl)ethylamine (1.1 g, 6.2 mmol), 4'-methoxyacetophenone (0.93 g, 6.2 mmol), titanium (IV) isopropoxide (2.2 g, 7.7 mmol), and EtOH (abs.) (1 mL) was heated to 60°C for 3 hours. Sodium cyanoborohydride (NaCNBH₃) (0.39 g, 6.2 mmol) was then added,
15 and the reaction mixture was stirred at room temperature for 18 hours. Ether (200 mL) and H₂O (2 mL) were added to the reaction mixture and the resulting precipitate was then removed by centrifugation. The supernatant was evaporated under vacuum and the crude product was chromatographed on
20 silica gel (25 mm x 25 cm column) (elution with 1% MeOH/CHCl₃). A portion of this material was HPLC chromatographed [Selectosil*, 5 μM silica gel; 25 cm x 10.0 mm (Phenomenex, Torrance, CA), 4 mL per minute; UV det. 275 nm; 12% ethyl acetate-88% hexane (elution time
25 12.0 min)]. The HPLC purified diastereomer was then dissolved in hexanes and ethereal HCl was added to precipitate the product as a white solid (20 mg), m.p.: 209-210°C (dec.).

*Trade-mark

79565-6

29a

Example 10: Synthesis of Compound 16M

N-(3-chloro-4-methoxybenzyl) - (*R*) - 1 - (1-naphthyl) ethylamine
hydrochloride

A mixture of (*R*) - (+) - 1 - (1-naphthyl) ethylamine
5 (6.6 g, 39 mmol), 3'-chloro-4'-methoxybenzaldehyde (6.6 g,
39 mmol), and titanium (IV) isopropoxide (13.8 g,
48.8 mmol), and EtOH (abs.) (30 mL) was heated to 80°C for
30 minutes

2173747

30

then allowed to stir at room temperature for 3 hours. Sodium cyanoborohydride (NaCNBH_3) (2.45 g, 39 mmol) was then added. The reaction mixture was stirred at room temperature for 18 hours. Ether (100 mL) and H_2O (2 mL) were added to the reaction mixture and the resulting precipitate was then removed by centrifugation. The supernatant was evaporated under vacuum and the crude product was chromatographed on silica gel (50 mm X 30 cm column) (elution with CH_2Cl_2). The chromatographed material was then dissolved in hexane (500 mL), decolorized with Norit® filtered (0.2 μM), and then ethereal HCl was added to precipitate the product as a white solid (10.2 g, 56 % yield), m.p.: 241-242°C (dec.).

Example 11: Synthesis of Compound 16P

15 *4-Methoxy-3-methylacetophenone [16P Precursor]*

A mixture of 4'-hydroxy-3'-methylacetophenone (5.0 g, 33.3 mmol), iodomethane (5.7 g, 40.0 mmol), K_2CO_3 (granular, anhydrous) (23.0 g, 167 mmol), and acetone (250 mL) was refluxed for 3 hours. The reaction mixture was then cooled to room temperature, filtered to remove the inorganic salts, and evaporated under vacuum. The crude product was dissolved in ether (100 mL) and washed with H_2O (2 x 20 mL). The organic layer was dried (Na_2SO_4) and evaporated to yield 4.5 g, 82.4% yield. The ketone was used in the following reaction without further purification.

(R)-N-(1-(4-Methoxy-3-methylphenyl)ethyl)-(R)-1-(1-naphthyl)ethylamine hydrochloride [Compound 16P]

A mixture of (R)-(+)-1-(1-naphthyl)ethylamine (4.24 g, 24.8 mmol), 4'-methoxy-3'-methylacetophenone (4.06 g, 24.8 mmol), and titanium (IV) isopropoxide (8.8 g, 30.9 mmol), and EtOH (abs.) (1 mL) was heated to 100°C for 2 hours. Isopropanol (45 mL) was added and the reaction was then cooled to 10°C in an ice bath. Sodium triacetoxymethylborohydride ($\text{NaHB}(\text{O}_2\text{CCH}_3)_3$) (10.5 g, 49.5 mmol)

2173747

31

was then added in portions over 15 minutes. The reaction mixture was then heated to 70°C for 18 hours. The mixture was cooled to room temperature and poured into ether (400 mL). The suspension was centrifuged, the supernatant was
5 collected and the pellet was washed with ether (400 mL). The combined organic washings were evaporated under vacuum. The residue was dissolved in ether (400 mL) and washed with 1 N NaOH (4 x 50 mL) and H₂O (2 x 50 mL). The organic layer was dried (Na₂SO₄), filtered and evaporated
10 under vacuum. EtOH (abs.) was added to the wet residue which was then dried thoroughly on a rotary evaporator to provide an oil. The mixture was then chromatographed on silica gel (50 mm x 30 cm) [elution with (1% MeOH:1% IPA:CHCl₃) to give 4.8 g of an oil].

15 The desired diastereomer was further purified by HPLC chromatography [SUPELCOSIL™ PLC-Si, 18 μM silica gel; 25 cm x 21.2 mm (Supelco, Inc., Bellefonte, PA), 7 mL per minute; UV det. 275 nm: 20% EtOAc-80% hexane (elution time 9.5 - 11.0 min)]. Injections (800 μL aliquots) of the
20 mixture (100 mg/mL solution in eluent) provided 65 mg of the desired isomer. Multiple HPLC injections provided 1.0 g of purified material. The HPLC chromatographed material was dissolved in hexane (50 mL) and the hydrochloride salt was precipitated with ethereal HCl. The salt was
25 collected on fritted glass and washed with hexane to provide 1.0 g of a white solid, mp 204-205°C.


Other embodiments are within the following claims.

79565-6

32

CLAIMS:

1. A compound having the formula:



10

wherein:

each Y is independently selected from the group consisting of isopropyl, CH₃O, CH₃S and a fused aromatic ring; and

- 15 n is independently an integer between 0 and 5 inclusive;

or a pharmaceutically acceptable salt or complex thereof.

2. The compound, salt or complex according to claim 1, wherein n is 0.

- 20 3. The compound, salt or complex according to claim 1, wherein n is 1.

4. The compound, salt or complex according to claim 3, wherein Y is CH₃O.


5. The compound, salt or complex according to claim 3, wherein Y is isopropyl.
- 25

6. The compound, salt or complex according to claim 3, wherein Y is CH₃S.


72459-13

33

7. The compound, salt or complex according to claim 1, wherein



8. A compound having the formula:



wherein:

each Y is independently selected from the group consisting of CH₃, CH₃O, CH₃CH₂O, methylene dioxy, Br, Cl, F, CF₃, CH₃S, OH, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl and a fused aromatic ring;

R is hydrogen or methyl; and

each n is independently an integer between 0 and 5 inclusive;

20 provided that (a) when R is H and n is 2, Y is not CH₃O and Br; or (b) when R is H and n is 2, Y is not CH₃CH₂O and Cl;

or a pharmaceutically acceptable salt or complex thereof.

72459-13

34

9. The compound, salt or complex of claim 8, wherein Y is a fused aromatic ring; R is hydrogen or methyl; and n is 1, 2, 3 or 4.

10. The compound, salt or complex of claim 8, wherein Y is isopropyl, CH₃O, CH₃S or a fused aromatic ring.


11. The compound, salt or complex of claim 8, 9 or 10, wherein R is H.

12. The compound, salt or complex of claim 8, 9 or 10, wherein R is methyl.

13. The compound, salt or complex of claim 8, 9, 10, 11 or 12, wherein n is 1 or 2.



14. The compound, salt or complex of claim 8, 9, 10, 11, 12 or 13, wherein

15




72459-13

35




10 15. A compound having the chemical formula:



15 or a pharmaceutically acceptable salt or complex thereof.

16. A compound having the chemical formula:



20

or a pharmaceutically acceptable salt or complex thereof.

72459-13

36

17. A pharmaceutical composition comprising:

the compound, salt or complex of any one of
claims 1 to 16, and

a pharmaceutically acceptable carrier.

5 18. The pharmaceutical composition of claim 17, which
is for treating a disease or disorder characterized by
abnormal calcium homeostasis.

19. The pharmaceutical composition of claim 18,
wherein the disease or disorder characterized by abnormal
10 calcium homeostasis is primary or secondary
hyperparathyroidism, Paget's disease, hypercalcemia,
osteoporosis or hypertension.

20. Use of the compound, salt or complex of any one of
claims 1 to 16 for the manufacture of a pharmaceutical
15 composition for treating a patient having a disease or
disorder characterized by abnormal calcium homeostasis.

21. Use of the compound, salt or complex of any one of
claims 1 to 16 for the manufacture of a pharmaceutical
composition for treating a disease or disorder selected from
20 the group consisting of primary or secondary
hyperparathyroidism, Paget's disease, hypercalcemia,
osteoporosis and hypertension.

22. A commercial package comprising the pharmaceutical
composition of claim 18 or 19, and instructions for the use
25 thereof for treating the disease or disorder.

SMART & BIGGAR
OTTAWA, CANADA

PATENT AGENTS

2173747

15.02.95

1/90









FIG. 1A.
RECTIFIED SHEET (RULE 91)
ISA/EP

2173747

15.02.95

2190








FIG. 1B.

RECTIFIED SHEET (RULE 91)
ISA/EP

2173747

92.95

3/90










FIG. 1C.

2173747







FIG. 1D.

2173747












FIG. 1E.


2173747

15.02.95


6190




2A



2B



2C




2D

FIG. 2A.


2173747

15.02.95


7/90




2E




2F



2G



2H




2I

FIG. 2B.


2173747

15.02.95


8/90




2J




2K




2L



2M



2N



2O

FIG. 2C.
RECTIFIED SHEET (RULE 91)
ISA/EP

2173747

15.02 95

9190









FIG. 2D.

2173747

J. UZ. 95

10/90











FIG. 3A.

2173747

13.02.95

11/90

**FIG. 3B.**

2173747

15.02.95

12/90









FIG. 3C.
RECTIFIED SHEET (RULE 91)
ISA/EP


2173747

15.02.95


13/90




3R




3S



3T



3U



3V

FIG. 3D.

2173747

14/90







FIG. 3E.

2173747

15/90










FIG. 4A.

RECTIFIED SHEET (RULE 91)
ISA/EP

2173747


15.02.95

16/90

**FIG. 4B.**RECTIFIED SHEET (RULE 91)
JSA/EP

2173747

17/90

**FIG. 4C.**RECTIFIED SHEET (RULE 91)
ISA/EP

2173747

15.02.95
18/90









FIG. 4D.


RECTIFIED SHEET (RULE 91)
ISA/EP

2173747


**FIG. 4E.**

2173747


20/90




5A




5B




5C



5D



5E



5F

FIG. 5A.

2173747

15.02.95

21/90




FIG. 5B.

RECTIFIED SHEET (RULE 91)
ISA/EP

15. 02. 95

2173747

22/90




FIG. 5C.

RECTIFIED SHEET (RULE 91)
ISA/EP

15.02.95

2173747

23/90









FIG. 5D.

15.02.95

2173747

24/90




FIG. 6A.

2173747

25/90









FIG. 6B.

15.02.95

2173747

26/90







FIG. 6C.

2173747

27/90








FIG. 6D.

2173747

28/90









FIG. 6E.


15.02.95

2173747


19/90




7A




7B




7C



7D



7E



7F

FIG. 7A.

15.02.95

30/90

2173747









FIG. 7B.

15.02.97

2173747

31/90









FIG. 7C.

RECTIFIED SHEET (RULE 91)
ISA/EP

2173747

30/90








FIG. 7D.

2173747

33/90





FIG. 7E.

15.02.95

2173747

34A0

**FIG. 8A.**RECTIFIED SHEET (RULE 91)
ISA/EP

15.02.95

2173747

35/90





FIG. 8B.


RECTIFIED SHEET (RULE 91)
ISA/EP

2173747


36/90




8L




8M



8N



8O



8P

FIG. 8C.

2173747

37/90




FIG. 8D.

2173747

38/90





FIG. 8E.

RECTIFIED SHEET (RULE 91)
ISA/EP

21737.47

39/90

**FIG. 9A.**RECTIFIED SHEET (RULE 91)
ISA/EP

2173747

40/90




FIG. 9B.

2173747

15.02.95
41/90




FIG. 9C.

2173747 42/90




FIG. 9D.

2173747

43/9D




FIG. 9E.

15.02.95

2173747

44/90




FIG. 9F.

RECTIFIED SHEET (RULE 91)
ISA/EP

2173747

15.02.95

45/90





FIG. 10A.


2173747

15.02.95


46/90




10H




10I




10J




10K



10L



10M




10N


FIG. 10B.

2173747


47/90




100




10P




10Q



10R



10S



10T

FIG.10C.

2173747

48/90




FIG. 10D.

2173747

49/90






FIG. 11A.

2173747


50/90




11F




11G



11H



11I



11J

FIG. 11B.

15.02.95
51/90

2173747















FIG. 11C.

2173747

**FIG. 11D.**RECTIFIED SHEET (RULE 91)
ISA/EP

2173747

1995

53/90








FIG. 11E.


2173747

15.02.95


54/90




12A




12B




12C




12D



12E



12F




12G

FIG. 12A.


2173747

15.02.95


55/90




12H




12I




12J




12K



12L



12M



RECTIFIED SHEET (RULE 91)
ISA/EP

FIG. 12B.

2173747

15. 02. 95

56/90











FIG. 12C.









FIG. 12D.

2173747

58/90




FIG. 13A.

RECTIFIED SHEET (RULE 91)
ISA/EP

2173747

15.02.95

59/90










FIG. 13B.



2173747

15.02.95

60/90





FIG. 13C.


2173747

1995.02.03


61/90




13U




13V




13W



13X



13Y



13Z

FIG. 13D.

RECTIFIED SHEET (RULE 91)
ISA/EP

2173747

5.02.95

62190










FIG. 14A.

2173747

13.02.95

63/90




FIG. 14B.

2173747

15.02.95

64/90










FIG. 14C.


2173747

15.02.95


65/90




14U




14V




14W



14X



14Y




14Z


FIG. 14D.

2173747


66/90




15A




15B




15C




15D



15E



15F



15G

FIG. 15A.

2173747

.5.02.95

67/90









FIG. 15B.

RECTIFIED SHEET (RULE 91)
ISA/EP

2173747

68/90 5.02.95









FIG. 15C.

2173747

3.02.95

69/90











FIG. 15D.


15.02.95

2173747


70/90




16A




16B




16C




16D



16E



16F



16G

FIG. 16A.

2173747

11/90

5.02.95
















FIG. 16B.



2173747

72/90

5.02.95

**FIG. 16C.**RECTIFIED SHEET (RULE 91)
ISA/EP

15.02.95

2173747

73/90












FIG. 16D.

RECTIFIED SHEET (RULE 91)
ISA/EP







2173747

74/90 15.02.95

**FIG. 17A.**

2173747

75/90 . . . 92.35

**FIG. 17B.**RECTIFIED SHEET (RULE 91)
ISA/EP

2173747

76/9D 15.02.95









FIG. 17C.

2173747

77/90

15.02.95











FIG. 17D.

2173747

15.02.95

18/90

**FIG. 18A.**

2173747

79/90

15.02.95










FIG. 18B.

2173747

80/90

15.02.95









FIG. 18C.


2173747

81/9D


15.02.95




17T




17U



17V



17W



17X

FIG. 18D.

2173747

82/90

15.02.95





FIG. 18E.

2173747

89/90

3.02.95




FIG. 19A.

2173747

84/90

15.02.95










FIG. 19B.

2173747

85/90

15.02.95









FIG. 19C.

2173747

86/90 11.02.95









FIG. 19D.

2173747

J. 02 95

87/90







FIG. 20A.

2173747

28/90 J. U. 95





FIG. 20B.

RECTIFIED SHEET (RULE 91)
ISA/EP


2173747

89/90


01.95




19I




19J




19K




19L



19M



19N



19O

FIG. 20C.

2173747

90/90 15.02.95










FIG. 20D.

